NDC product
Desvenlafaxine Succinate
NDC 33342-389 · Macleods Pharmaceuticals Limited
Key facts
| Product NDC | 33342-389 |
|---|---|
| Proprietary name | Desvenlafaxine Succinate |
| Nonproprietary name | Desvenlafaxine Succinate |
| Substances | DESVENLAFAXINE SUCCINATE |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Labeler | Macleods Pharmaceuticals Limited |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA211427 |
| Pharmacologic classes | Cytochrome P450 2D6 Inhibitors [MoA], Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC] |
| Marketing start | Jun 16, 2018 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: